ImmunoPrecise Antibodies (IPA) to Release Earnings on Thursday

Posted by Defense World Staff on Mar 6th, 2025

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last announced its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunoPrecise Antibodies Stock Up 11.7 %

ImmunoPrecise Antibodies stock opened at $0.39 on Thursday. The stock has a market cap of $12.24 million, a PE ratio of -0.51 and a beta of 0.09. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. ImmunoPrecise Antibodies has a one year low of $0.27 and a one year high of $2.43. The stock has a fifty day moving average of $0.46 and a 200 day moving average of $0.52.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their price objective on ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th.

Read Our Latest Stock Analysis on ImmunoPrecise Antibodies

About ImmunoPrecise Antibodies

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.